phase readout
saveNCT07074886: A Study to Assess Bioequivalence of Two Subcutaneous (SC) Formulations of Ocrelizumab in Participants With Multiple Sclerosis (MS)
ACTIVE_NOT_RECRUITINGupdated 17m ago
community read0 votes
Sponsor: Hoffmann-La Roche. Phase: PHASE2. Conditions: Multiple Sclerosis
view source ↗
comments(0)
5-min edit window · permanent after that